Abstract: A polymeric compound is disclosed herein, having the general formula I: wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

Abstract: A genetically modified human beta-glucocerebrosidase (GCase) is disclosed. The genetically modified GCase comprising an amino acid sequence at least 85% identical to SEQ ID NO: 2; and comprising mutations at coordinates L34P, K224N/G, T369E and N370D, where the coordinates correspond to said SEQ ID NO: 2; and capable of catalyzing hydrolysis of a glycolipid glucosylceramide (GlcCer). Pharmaceutical compositions comprising the genetically modified GCase and therapeutic methods of using same are also disclosed.

Abstract: This invention is directed to His-tag binding compounds and uses thereof in the preparation of genetically targeted detectable molecules and sensors which can specifically bind tag-labeled proteins. This invention further provides a system comprising recombinant cells decorated with various labels and/or synthetic agents, wherein said labels and/or synthetic agents can be reversibly modified or removed from the cells. Also disclosed herein are methods for decorating and/or modifying the cells and methods for using thereof.

Abstract: Embodiments pertain to ureteral stents for treatment of partial or full ureteral occlusion by bridging one or more ureteral occlusions, where each stent includes a tubular portion, a first spout portion and a second spout portion. The stent may have one or more tapered edges by having the smallest diameter of the first and/or the second spout portion smaller than the largest diameter of the tubular portion, and/or be of an overall length allowing the ureteral stent to be completely located within a patient's ureter once deployed therein.

Abstract: Disclosed herein are anti-CTLA-4 antibodies possessing superior binding and biological activities relative to ipibmumab and tremelimumab, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-CTLA-4 antibodies.

Abstract: A method of reducing a friction coefficient of a surface is disclosed herein, comprising attaching a water-soluble polymer to the surface, and contacting the water-soluble polymer with liposomes, thereby coating the surface with an amphiphilic lipid. Further disclosed herein are solutions comprising a water-soluble polymer attachable to the surface, liposomes, and an aqueous carrier, for reducing a friction coefficient of a surface, and methods utilizing same. Articles of manufacture comprising a substrate coated by a water-soluble polymer which is coated by an amphiphilic lipid are also described, as are uses and methods for treating a synovial joint disorder associated with increased articular friction.

Abstract: Described herein are anti-human Grp94 antibodies. The antibodies may be used to target senescent cells. Thus, the anti-Grp94 antibodies would be useful in treating diseases and conditions associated with cellular senescence. The anti-Grp94 antibodies could target senescent cells in vivo. Therefore, the anti-Grp94 antibodies could be used to target senescent cells associated with age-related diseases in vivo.

Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.

Abstract: The invention provides a method for lubricating one or more surfaces, comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature Tm of said liposomes. The method can be used for lubricating non-biological surfaces, and also for lubricating the surfaces of a biological tissue in a mammalian subject, e.g., for treating joint dysfunction.

Abstract: A method of identifying a molecular composition and a spatial position of a single cell comprised in a 3 dimensional structure comprising a plurality of cells is provided.

Abstract: Disclosed herein are 3, 4-didehydro- and 3?-deoxy-3, 4-didehydro-compounds and pharmaceutical compositions thereof. Methods of use of these pharmaceutical compositions include those for treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SAR-CoV-2, EBV, BKV, JCV and HCMV.

Abstract: A method of predicting an analyte level comprises receiving a time-ordered series of levels of the analyte, monitored over a time-period; feeding a trained neural network procedure with the monitored levels; and displaying, based on an output received from the procedure, a predicted level of the analyte in a future time. The procedure can comprise a plurality of layers, wherein for at least one pair of layers, a number of inter-layer connections within the pair is higher for later monitored levels than for earlier monitored levels.

Abstract: A prosodic speech recognition engine configured to identify prosodic features and patterns in a speech continuum for the extraction of linguistic content including para-syntactic content, discourse function, information structure, meaning, and speaker sentiment.

Abstract: An article of manufacture is provided. The article of manufacture comprising a first binding moiety which specifically binds a human FcgamaRIIB and blocks interaction with IgG antibodies and a second binding moiety which specifically binds a human PD-L1, wherein the second binding moiety which specifically binds the human PD-L1 is an antibody of a human IgG1 isotype.

Abstract: A downloadable navigator for a mobile ultrasound unit having an ultrasound probe, implemented on a portable computing device. The navigator includes a trained orientation neural network to receive a non-canonical image of a body part from the mobile ultrasound unit and to generate a transformation associated with the non-canonical image, the transformation transforming from a position and rotation associated with a canonical image to a position and rotation associated with the non-canonical image; and a result converter to convert the transformation into orientation instructions for a user of the probe and to provide and display the orientation instructions to the user to change the position and rotation of the probe.

Abstract: A device for controlling respiration during sleep based on the user physiological characteristic. The device includes an odor disperser for dispersing an odor; at least one detector for detecting a physiological characteristic of a user; and a controller for controlling respiration of the user by instructing the odor dispenser to disperse an odor responsive to detections by the at least one detector.

Abstract: Assays and methods for diagnosing and treating autoimmune diseases. Particularly, the invention provides methods for differential diagnosis of specific autoimmune diseases, including autoimmune rheumatic disorders.

Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.

Abstract: A reflective optical system (100) comprising at least one reflective aspheric surface (1) of focal length f0 and optical axis (Z), the surface being configured so that an incident laser beam (2) propagating along an axis (Z?) is focused along the optical axis (Z) with a FWHM ((Full Width at Half Maximum) of the intensity of the reflected beam along the optical axis (Z) being larger, preferably by a factor of at least 10, than the FWHM of the intensity of a focused beam reflected by a parabola having same focal length f0 and same optical axis (Z), receiving same beam.

Abstract: Disclosed herein are genetically modified plants expressing multiple animal milk proteins. Further disclosed are vectors for expressing in a plant and parts thereof, multiple mammalian milk proteins; genetically modified and or gene-edited plants having at least one cell expressing and producing at least two recombinant mammalian milk proteins wherein expression may be in a seed, bean, grain, fruit, nut, legume, leaf, stem, root, or portion thereof, the recombinant protein being produced by the plant cell; and a method of producing a food, medicament, cosmetic or blocking composition from the genetically modified or gene-edited plant. Reduction or elimination of seed storage proteins in a cell or cells wherein the milk proteins are expressed, or reduction of plant enzymes that can increase the content of oleic and/or stearic fatty acids and/or reduce the content of saturated fats in the plants or plant products are also disclosed.